Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-04-05
2008-12-09
Berch, Mark L (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S221000, C544S279000
Reexamination Certificate
active
07462621
ABSTRACT:
The invention relates to an use of pyrimidone derivative represented by formula (I) or a salt thereof:wherein m, n, p, X, Y, R1, R2, R3, R4 and R5 are as defined herein for treating a variety of disease states. More specifically, the invention relates to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β or GSK3β and cdk5/p25, such as Alzheimer's disease.
REFERENCES:
patent: 7214682 (2007-05-01), Gallet et al.
patent: WO 98/16528 (1998-04-01), None
patent: WO 98/24780 (1998-06-01), None
patent: WO 99/65897 (1999-12-01), None
patent: WO 00/18758 (2000-04-01), None
patent: WO 01/42224 (2001-06-01), None
patent: WO 01/44246 (2001-06-01), None
Wagman (Curr. Pharm. Des.) , 2004, 10, 1105-1137.martin.
Martinez, et al., Med. Res. Rev., vol. 22, No. 4, 373-384 (2002).
Buee, et al., Brain Res. Rev., 33 (2000) 95-130.
Henriksen, et al., Curr. Drug Targets, Nov. 2006, 7 (11), 1435-42 (Abstract).
Abstract of Gould et at. Curr. Drug Targets, Nov. 2006, 7(11): 1399-409.
Abstract of Zhao et al., Schizophr. Res., 206 May; 84(1). Epub Apr. 11, 2006.
Abstract of Gould, Expert Opin. Ther. Targets, Jun. 2006; 10(3):377-92.
Kwok, et al., Annals of Neurology, vol. 58, No. 6, Dec. 2005, pp. 829-839.
Nadri, et al., Schizophrenia Research, 71 (2004), 377-382.
Bhat, R.V., et. al., Glycogen Synthase Kinase 3: A drug Target for CNS Therapies, Journal of Neurochemistry, vol. 89, (2004), pp. 1313-1317.
Harwood, A.J., et. al., Neurodevelopment and Mood Stabilizers, PubMed abstract of Curr. Mol. Med. (2003) Aug; vol. 3, No. 5 pp. 472-482.
Leclerc, S., et. al., Indirubins Inhibit Glycogen synthase Kinase-3B and CDK5/P25, Two Protein Kinases Involved in Abnormal Tau Phosporylation in alzheimer's Disease , The Journal of Biological Chemistry, vol. 276, No. 1, (2001), pp. 251-260.
Souillac, P., et. al., Characterization of Delivery Systems, Differential Scanning Calorimetry, Encyclopedia of Controlled Drug Delivery, (1999), John Wiley & Sons, pp. 212-227.
Derivative (chemistry), retrieved from “http://en.wikipedia.org/wiki/Derivative-%28chemistry%29” on Aug. 10, 2006.
List of Neurodegenerative Diseases, From Wikipedia, Nov. 2006.
List of Neurodegenerative Diseases, From the University of California, Nov. 2006.
Gallet Thierry
Lardenois Patrick
Lochead Alistair
Marguerie Séverine
Nedelec Alain
Berch Mark L
Gupta Balaram
Jaisle Cecilia M
Mitsubishi Pharma Corporation
Sanofi-Aventis
LandOfFree
Use of substituted... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of substituted..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of substituted... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4030420